Your browser is no longer supported. Please, upgrade your browser.
Zynerba Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.04 Insider Own0.10% Shs Outstand40.09M Perf Week-4.94%
Market Cap103.47M Forward P/E- EPS next Y-0.99 Insider Trans0.00% Shs Float39.21M Perf Month-22.12%
Income-38.10M PEG- EPS next Q-0.26 Inst Own36.20% Short Float8.00% Perf Quarter-35.40%
Sales- P/S- EPS this Y-26.90% Inst Trans7.90% Short Ratio2.80 Perf Half Y-44.69%
Book/sh1.96 P/B1.28 EPS next Y-4.10% ROA-41.10% Target Price7.10 Perf Year-30.75%
Cash/sh1.83 P/C1.37 EPS next 5Y- ROE-47.30% 52W Range2.21 - 9.00 Perf YTD-13.19%
Dividend- P/FCF- EPS past 5Y7.60% ROI- 52W High-72.61% Beta2.23
Dividend %- Quick Ratio8.10 Sales past 5Y- Gross Margin- 52W Low11.54% ATR0.17
Employees26 Current Ratio8.10 Sales Q/Q- Oper. Margin- RSI (14)33.24 Volatility8.04% 6.28%
OptionableYes Debt/Eq0.00 EPS Q/Q14.70% Profit Margin- Rel Volume0.88 Prev Close2.50
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.12M Price2.46
Recom2.00 SMA20-9.17% SMA50-23.05% SMA200-41.14% Volume914,201 Change-1.40%
Dec-21-20Reiterated H.C. Wainwright Buy $12 → $9
Jul-01-20Downgrade Needham Buy → Hold
Dec-31-19Resumed ROTH Capital Buy $12
Oct-21-19Initiated Needham Buy $18
Apr-22-19Resumed Canaccord Genuity Buy
Feb-01-18Resumed H.C. Wainwright Buy $23
Jan-29-18Initiated Ladenburg Thalmann Buy $25.50
Jan-26-18Initiated Seaport Global Securities Buy $16
Oct-02-17Upgrade Cantor Fitzgerald Neutral → Overweight $4 → $17
Sep-29-17Upgrade Piper Jaffray Neutral → Overweight
Aug-15-17Upgrade ROTH Capital Neutral → Buy
Aug-15-17Downgrade Oppenheimer Outperform → Perform
Aug-15-17Downgrade Jefferies Buy → Hold
Aug-08-17Downgrade ROTH Capital Buy → Neutral
Aug-08-17Downgrade H.C. Wainwright Buy → Neutral $7
Aug-07-17Downgrade Piper Jaffray Overweight → Neutral
Aug-07-17Downgrade Maxim Group Buy → Hold
Aug-07-17Downgrade Cantor Fitzgerald Overweight → Neutral $28 → $4
Mar-28-17Reiterated H.C. Wainwright Buy $22 → $30
Feb-24-17Initiated Maxim Group Buy $32
Jan-06-22 07:00AM  
Jan-05-22 06:29AM  
Jan-04-22 04:05PM  
Dec-06-21 07:00AM  
Nov-22-21 07:00AM  
Nov-15-21 07:00AM  
Oct-21-21 07:00AM  
Oct-19-21 04:15PM  
Oct-08-21 07:30AM  
Sep-20-21 07:00AM  
Sep-13-21 07:00AM  
Sep-09-21 11:06AM  
Sep-07-21 07:00AM  
Sep-02-21 07:30AM  
Aug-09-21 07:00AM  
Aug-04-21 07:30AM  
Aug-02-21 01:31PM  
Jul-07-21 07:30AM  
Jun-30-21 07:00AM  
Jun-29-21 09:01AM  
Jun-11-21 02:44PM  
Jun-09-21 04:05PM  
Jun-07-21 08:00AM  
Jun-04-21 07:30AM  
Jun-03-21 10:00AM  
May-27-21 07:30AM  
May-26-21 07:30AM  
May-17-21 08:00AM  
May-12-21 06:45AM  
May-06-21 07:53AM  
May-05-21 04:05PM  
Apr-29-21 02:00PM  
Apr-15-21 07:30AM  
Apr-06-21 07:30AM  
Mar-31-21 12:15PM  
Mar-28-21 08:15AM  
Mar-12-21 05:22AM  
Mar-10-21 06:45AM  
Mar-05-21 05:50PM  
Mar-04-21 08:00AM  
Feb-26-21 05:50PM  
Feb-11-21 11:29AM  
Feb-03-21 04:25PM  
Jan-04-21 07:30AM  
Dec-23-20 05:30AM  
Dec-17-20 08:10AM  
Dec-09-20 03:49PM  
Dec-08-20 06:00AM  
Dec-07-20 12:00PM  
Dec-04-20 11:30AM  
Dec-03-20 09:27PM  
Nov-23-20 11:45AM  
Nov-09-20 11:20AM  
Oct-16-20 11:01AM  
Oct-15-20 03:06PM  
Oct-08-20 08:32AM  
Sep-23-20 02:37PM  
Sep-18-20 08:51AM  
Sep-17-20 01:55PM  
Sep-14-20 06:55AM  
Sep-10-20 07:30AM  
Aug-10-20 06:45AM  
Aug-06-20 07:00AM  
Jul-29-20 05:50PM  
Jul-24-20 10:16AM  
Jul-22-20 06:50AM  
Jul-05-20 02:00PM  
Jul-01-20 09:36AM  
Jun-30-20 07:57AM  
Jun-29-20 08:57AM  
Jun-25-20 11:26AM  
Jun-17-20 09:43AM  
Jun-15-20 08:53PM  
May-27-20 06:45AM  
May-26-20 06:52AM  
May-25-20 11:30AM  
May-22-20 07:30AM  
May-21-20 08:00AM  
May-11-20 06:50AM  
Apr-28-20 01:01PM  
Apr-10-20 08:00AM  
Apr-02-20 05:45PM  
Mar-25-20 05:50PM  
Mar-10-20 06:50AM  
Mar-09-20 08:30AM  
Mar-05-20 08:30AM  
Mar-03-20 12:08PM  
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It improves the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.